The predators who run the pharmaceutical industry have another thing coming in 2025 when RFK Jr., God willing, takes over the reins at the HHS, by hook or by crook.
The bipartisan cadre of Swamp creatures in Washington on the industry take are sure to oppose his nomination tooth and nail, but hopefully Trump can figure out how to get him appointed on a provisional basis that eventually turns into a de facto permanent basis.
Related: RFK Jr. Threatens War on FDA in Epic Tweet
To counter the MAHA agenda, Eli Lilly CEO David Ricks, valiant defender of not just his shareholders’ bottom lines but of The Science™, has nobly pledged himself and his corporation worth three-quarters of a trillion dollars to resist the recently expressed democratic will of the American people.
Because Democracy™, and because Public Health™.
Via The New York Times (emphasis added):
President-elect Donald J. Trump’s pick of Robert F. Kennedy Jr., a longtime vaccine skeptic with no medical or public health training, to be the next health secretary has sent a chill through the American public health sphere.
Among drugmakers, there are already signs of pushback.
David Ricks, the chair and chief executive of Eli Lilly, speaking at The New York Times’s DealBook Summit, said his $750 billion company would fight to defend preserving the Food and Drug Administration as it stands today.
Ricks was also out in the public domain recently claiming that Eli’s historically lucrative drugs Mounjaro and Zepbound are, beyond just weight loss miracles sent from heaven, something called “anti-hedonics,” which means apparently that they can cure any addiction or compulsion, including drug addiction.
Via StatNews (emphasis added):
Eli Lilly, the company that makes the blockbuster weight loss treatment Zepbound, will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major drugmaker to do so, CEO David Ricks said Tuesday.
Emerging research suggests that GLP-1 drugs — Zepbound is one such treatment — not only reduce food cravings but may also suppress desires for other substances. Yet, so far, no pharma companies have tested the therapies specifically in addiction.
“These medicines, we think and we’ve aimed to prove, can be useful for other things we don’t think about connected to weight. These are often called anti-hedonics*, so they are reducing that desire cycle, said Ricks.
Confucius say: in order to cure drug addiction, one must turn to expensive drugs — and get the government to foot the bill so drug companies can sell even to the poors with no disposable income.
Related: Feds Propose MASSIVE, Budget-Breaking Subsidy For Ozempic, Mounjaro as Pharma Stocks Surge
Make it make sense, please.
“We’re starting to look at different use case scenarios, um, things like alcohol use disorder or opioid use disorder. We also are talking about things like Parkinsonism, Alzheimer’s disease. So we’re going to see different disease processes begin to come into the mix when we’re looking at GLP-1 receptor agonists that get outside of the cardiometabolic sphere,” says industry hack Dr. Fatima Cody Stanford. As I have previously reported, Dr. Stanford is literally a paid shill who regularly appears in the corporate media to hawk these drugs without ever telling viewers that she is receiving cash for her propaganda work
Profiles in integrity.
